ATE307810T1 - Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren - Google Patents

Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren

Info

Publication number
ATE307810T1
ATE307810T1 AT02771674T AT02771674T ATE307810T1 AT E307810 T1 ATE307810 T1 AT E307810T1 AT 02771674 T AT02771674 T AT 02771674T AT 02771674 T AT02771674 T AT 02771674T AT E307810 T1 ATE307810 T1 AT E307810T1
Authority
AT
Austria
Prior art keywords
kinase inhibitors
raf
imidazole
acid amide
carbonic acid
Prior art date
Application number
AT02771674T
Other languages
English (en)
Inventor
David Kenneth Dean
Andrew Kenneth Takle
David Matthew Wilson
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE307810T1 publication Critical patent/ATE307810T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT02771674T 2001-05-19 2002-05-20 Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren ATE307810T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0112348.8A GB0112348D0 (en) 2001-05-19 2001-05-19 Compounds
PCT/GB2002/002353 WO2002094808A1 (en) 2001-05-19 2002-05-20 Imidazole-2-carboxamide derivatives as raf kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE307810T1 true ATE307810T1 (de) 2005-11-15

Family

ID=9915014

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02771674T ATE307810T1 (de) 2001-05-19 2002-05-20 Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren

Country Status (8)

Country Link
US (2) US7282500B2 (de)
EP (1) EP1397354B1 (de)
JP (1) JP2004529967A (de)
AT (1) ATE307810T1 (de)
DE (1) DE60206911T2 (de)
ES (1) ES2248610T3 (de)
GB (1) GB0112348D0 (de)
WO (1) WO2002094808A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189745B1 (en) 1999-11-22 2007-03-13 Smithkline Beecham Corporation Compounds
DE60103136T2 (de) * 2000-03-06 2004-10-28 Smithkline Beecham Plc, Brentford Imidazolderivate als Raf-Kinase Inhibitoren
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
EP1432703A1 (de) * 2001-09-05 2004-06-30 Smithkline Beecham Plc Heterocycle-carboxamide derivate als raf kinase inhibitoren
ATE447404T1 (de) 2002-03-29 2009-11-15 Novartis Vaccines & Diagnostic Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
EP2258365B1 (de) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Verwendung von organischen verbindungen zur immunstärkung
JP4755991B2 (ja) 2003-10-16 2011-08-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｒａｆキナーゼインヒビターとしての置換ベンゾアゾールおよびその使用
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
RU2007147382A (ru) * 2005-05-20 2009-06-27 Эррэй Биофарма Инк. (Us) Соединения, являющиеся ингибиторами raf, и способы их применения
CL2008001626A1 (es) 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JP5270553B2 (ja) 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
JP5350247B2 (ja) 2007-08-29 2013-11-27 武田薬品工業株式会社 複素環化合物およびその用途
EP2265610B1 (de) 2008-02-29 2012-12-12 Array Biopharma, Inc. Pyrazol[3,4-b]pyridin-raf-inhibitoren
EP2265574A1 (de) 2008-02-29 2010-12-29 Array Biopharma, Inc. N-(6-aminopyridin-3-yl)-3-(sulfonamido)benzamidderivate als b-raf-inhibitoren zur behandlung von krebs
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
JP2013503190A (ja) 2009-08-28 2013-01-31 アレイ バイオファーマ、インコーポレイテッド Ｒａｆ阻害化合物およびその使用方法
JP2013503189A (ja) 2009-08-28 2013-01-31 アレイ バイオファーマ、インコーポレイテッド Ｒａｆ阻害化合物およびその使用方法
SG178899A1 (en) 2009-08-28 2012-04-27 Array Biopharma Inc Raf inhibitor compounds and methods of use thereof
CN102666498A (zh) 2009-08-28 2012-09-12 健泰科生物技术公司 Raf抑制剂化合物及其使用方法
EP2470538A1 (de) 2009-08-28 2012-07-04 Array Biopharma, Inc. Raf-hemmende verbindungen und anwendungsverfahren dafür
CA2772316A1 (en) 2009-08-28 2011-03-03 Array Biopharma Inc. 1h-pyrazolo [3,4-b] pyridine compounds for inhibiting raf kinase
EP3028699B1 (de) 2010-02-25 2018-03-21 Dana-Farber Cancer Institute, Inc. Braf-mutationen für resistenz gegen braf-inhibitoren
EP2627650A2 (de) 2010-05-26 2013-08-21 Merck Sharp & Dohme Corp. N-phenyl-imidazol-carboxamid-hemmer von 3-phosphoinositidabhängiger proteinkinase-1
WO2012118492A1 (en) 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
EP3515446B1 (de) 2016-09-19 2023-12-20 Novartis AG Therapeutische kombinationen mit einem raf-hemmer und einem erk-hemmer
US11266653B2 (en) 2017-05-02 2022-03-08 Novartis Ag Combination therapy
ES3025633T3 (en) 2019-05-13 2025-06-09 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) * 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3940486A (en) * 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4348404A (en) * 1980-07-21 1982-09-07 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-α-polyfluoroalkyl-1H-imidazole-2-methanamines
CA1175431A (en) * 1980-07-25 1984-10-02 Alfred Sallmann Tri-substituted imidazole derivatives, processes for their manufacture, pharmaceutical preparations containing them, and their use
US4735958A (en) * 1986-12-22 1988-04-05 Warner-Lambert Company Trans-6-[2-[2-(substituted-phenyl)-3- (or 4-) heteroaryl-5-substituted-1H-pyrrol-1-yl]-ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one inhibitors of cholesterol biosynthesis
US5166214A (en) * 1988-12-05 1992-11-24 Du Pont Merck Pharmaceutical Company Use of imidazoles for the treatment of atherosclerosis
US5236917A (en) * 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
DE3935514A1 (de) 1989-10-25 1991-05-02 Boehringer Mannheim Gmbh Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
WO1992002257A2 (en) * 1990-08-10 1992-02-20 G.D. Searle & Co. Renal-selective angiotensin ii antagonists for treatment of hypertension
FR2673628B1 (fr) * 1991-03-07 1993-07-09 Esteve Labor Dr Procede de preparation de derives d'aryl (ou heteroaryl)-piperazinyl-butyl-azoles.
US5861420A (en) * 1991-04-05 1999-01-19 G. D. Searle & Co. N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
US5179117A (en) * 1991-12-20 1993-01-12 Du Pont Merck Pharmaceutical Company Antihypercholesterolemic 2-substituted imidazoles
US6008235A (en) * 1992-01-13 1999-12-28 Smithkline Beecham Corporation Pyridyl substituted imidazoles
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
US5310748A (en) 1992-05-11 1994-05-10 The Du Pont Merck Pharmaceutical Company Imidazoles for the treatment of atherosclerosis
US5593991A (en) * 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
AU7629594A (en) 1993-07-21 1995-02-20 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease
DE69401486T2 (de) * 1993-11-12 1997-04-30 Ishihara Sangyo Kaisha Verfahren zur Herstellung 2-cyanoimidazol Derivate
US5733882A (en) * 1994-01-17 1998-03-31 Smithkline Beecham Corporation Retroviral protease inhibitors
US5665753A (en) * 1994-03-03 1997-09-09 Smithkline Beecham Corporation Cytokine inhibiting imidazole substituted hydroxamic acid derivatives
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5514505A (en) * 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
CA2224563A1 (en) 1995-06-12 1996-12-27 G.D. Searle & Co. Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
US5837719A (en) * 1995-08-10 1998-11-17 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
AU699148B2 (en) 1995-08-10 1998-11-26 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5792778A (en) * 1995-08-10 1998-08-11 Merck & Co., Inc. 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
DE69637948D1 (de) 1995-10-06 2009-07-23 Merck & Co Inc Substituierte imidazole mit krebsremmender und cytokininhibierender wirkung
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GB2306108A (en) * 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
WO1997016442A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
WO1997016441A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Substituted aryl pyrroles, compositions containing such compounds and methods of use
JP2000502354A (ja) 1995-12-29 2000-02-29 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体アンタゴニスト
WO1997028160A1 (en) * 1996-02-01 1997-08-07 Smithkline Beecham Corporation Endothelin receptor antagonists
DK0880363T3 (da) 1996-02-13 2003-01-20 Searle & Co Kombinationer der omfatter en cyclooxygenase-2 hæmmer samt en leukotrien A4 hydrolasehæmmer, som har immunsuppressive virkninger
EP1640003A2 (de) 1996-02-13 2006-03-29 G.D. SEARLE & CO. Zubereitungen enthaltend einen cyclooxygenase-2-Inhibitor und einen leukotrien-b4-Rezeptor Antagonisten
WO1997035855A1 (en) 1996-03-25 1997-10-02 Smithkline Beecham Corporation Novel treatment for cns injuries
JP2000504023A (ja) 1996-04-03 2000-04-04 メルク エンド カンパニー インコーポレーテッド 癌治療方法
EP0906307B1 (de) * 1996-06-10 2005-04-27 Merck & Co., Inc. Substituierte imidazole mit cytokinin-inhibirender wirkung
WO1997048672A2 (en) 1996-06-21 1997-12-24 Allergan Sales, Inc. Substituted tetrahydronaphthalene and dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
WO1998013278A1 (de) 1996-09-27 1998-04-02 Merkler, H. Tank für flüssigkeiten, insbesondere für chemisch aggressive flüssigkeiten
WO1998016227A1 (en) 1996-10-15 1998-04-23 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US5776954A (en) * 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
BR9712720A (pt) 1996-10-30 1999-10-26 Schering Corp Derivados de piperazina como antagÈnicos de neurocinina
DE69728688T2 (de) * 1996-11-19 2004-08-19 Amgen Inc., Thousand Oaks Aryl und heteroaryl substituierte kondensierte pyrrole als entzündunghemmende mittel
US5880139A (en) * 1996-11-20 1999-03-09 Merck & Co., Inc. Triaryl substituted imidazoles as glucagon antagonists
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6608060B1 (en) * 1996-12-18 2003-08-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5945418A (en) * 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
CA2297176A1 (en) * 1997-04-24 1998-10-29 Ortho-Mcneil Pharmaceutical, Inc. Substituted imidazoles useful in the treatment of inflammatory diseases
WO1998047899A1 (en) 1997-04-24 1998-10-29 Ortho-Mcneil Corporation, Inc. Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
AR037061A1 (es) * 1997-05-22 2004-10-20 Searle & Co Compuesto derivado de pirazol sustituido, procesos para preparar dicho compuesto, composicion farmaceutica que lo contiene y su uso en la preparacion de medicamentos
JP2002502380A (ja) * 1997-05-22 2002-01-22 ジー．ディー．サール アンド カンパニー ｐ３８キナーゼ阻害剤としてのピラゾール誘導体
US6087496A (en) * 1998-05-22 2000-07-11 G. D. Searle & Co. Substituted pyrazoles suitable as p38 kinase inhibitors
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6979686B1 (en) * 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
AU7585498A (en) 1997-05-23 1998-12-11 Bayer Corporation Inhibition of p38 kinase activity by aryl ureas
EP0988301B1 (de) * 1997-06-12 2006-08-09 Aventis Pharma Limited Imidazolyl-cyclische acetale
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
US6040320A (en) * 1997-06-30 2000-03-21 Ortho-Mcneil Pharmaceutical, Inc. 2-substituted imidazoles useful in the treatment of inflammatory diseases
US5939421A (en) * 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
CA2306870A1 (en) 1997-10-20 1999-04-29 David Michael Goldstein Bicyclic kinase inhibitors
ATE257703T1 (de) * 1997-10-27 2004-01-15 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
EP1031572A4 (de) 1997-11-14 2001-09-19 Sankyo Co Pyridylpyrrol-derivate
EP1049664B1 (de) 1997-12-22 2005-03-16 Bayer Pharmaceuticals Corporation Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
SK285371B6 (sk) 1997-12-22 2006-12-07 Bayer Corporation Aryl- a heteroaryl-substituované heterocyklické močoviny, ich použitie a farmaceutické kompozície sich obsahom
JPH11246437A (ja) 1998-03-05 1999-09-14 Yoshitomi Pharmaceut Ind Ltd 消化管粘膜保護剤
NZ526958A (en) 1998-05-22 2004-12-24 Smithkline Beecham Corp Novel 2-alkyl substituted imidazole compounds
CA2332178A1 (en) * 1998-07-01 2000-01-13 Takeda Chemical Industries, Ltd. Retinoid-associated receptor function regulating agent
AU4395399A (en) 1998-07-02 2000-01-24 Sankyo Company Limited Five-membered heteroaryl compounds
ATE355856T1 (de) 1998-07-30 2007-03-15 Point Biomedical Corp Neuer wirkstoffträger für die gefriertrocknung von wässrigen suspensionen von mikropartikeln
US6207687B1 (en) * 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
AU6476599A (en) 1998-11-03 2000-05-22 Novartis Ag Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles
US6548503B1 (en) 1998-11-04 2003-04-15 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
AU2164300A (en) 1998-12-04 2000-06-26 N.V. Organon Substituted thiazoles for treatment of human diseases involving modulators of p-, l- and e- selectin
AU4556800A (en) 1999-04-27 2000-11-10 Smithkline Beecham Plc Novel treatment
DE60026350T2 (de) 1999-11-12 2006-11-09 Merck & Co., Inc. Diaryl piperidyl-pyrrol-derivate als antiprotozoenmittel
AU1596101A (en) 1999-11-12 2001-06-06 Merck & Co., Inc. Aliphatic amine substituted piperidyl diaryl pyrrole derivatives as antiprotozoal agents
US7189745B1 (en) 1999-11-22 2007-03-13 Smithkline Beecham Corporation Compounds
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
DE60103136T2 (de) * 2000-03-06 2004-10-28 Smithkline Beecham Plc, Brentford Imidazolderivate als Raf-Kinase Inhibitoren
US6353336B1 (en) * 2000-03-24 2002-03-05 Cypress Semiconductor Corp. Electrical ID method for output driver
JP2002037784A (ja) 2000-05-17 2002-02-06 Nikken Chem Co Ltd 新規チオフェンアミド化合物
WO2002024680A1 (en) * 2000-09-21 2002-03-28 Smithkline Beecham P.L.C. Imidazole derivatives as raf kinase inhibitors
WO2002039954A2 (en) 2000-11-20 2002-05-23 Smithkline Beecham Corporation Novel compounds
WO2002057255A1 (en) 2001-01-22 2002-07-25 Sankyo Company, Limited 4- or 5-substituted pyrrole derivatives
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
EP1432703A1 (de) * 2001-09-05 2004-06-30 Smithkline Beecham Plc Heterocycle-carboxamide derivate als raf kinase inhibitoren
EP1432699A1 (de) 2001-09-05 2004-06-30 Smithkline Beecham Plc Pyridylfurane und -pyrrole als raf-kinasehemmer
GB0121490D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Ciompounds
GB0121488D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
DE60228098D1 (de) * 2001-09-05 2008-09-18 Smithkline Beecham Plc Pyridin-substituierte furanderivate als raf-kinase inhibitoren
GB0121494D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
DE10145254A1 (de) 2001-09-13 2003-04-10 November Ag Molekulare Medizin Verwendung eines Proteins zur Herstellung eines Medikaments zur Stimulierung einer inflammatorischen zellulären Immunantwort

Also Published As

Publication number Publication date
DE60206911D1 (de) 2005-12-01
US20080108615A1 (en) 2008-05-08
US7282500B2 (en) 2007-10-16
US20040127496A1 (en) 2004-07-01
DE60206911T2 (de) 2006-07-20
GB0112348D0 (en) 2001-07-11
JP2004529967A (ja) 2004-09-30
WO2002094808A1 (en) 2002-11-28
EP1397354B1 (de) 2005-10-26
ES2248610T3 (es) 2006-03-16
EP1397354A1 (de) 2004-03-17

Similar Documents

Publication Publication Date Title
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
EA200700099A1 (ru) Производные пиридина
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
DE60140814D1 (de) N-phenyl-2-pyrimidine-amine derivatives
EA200400073A1 (ru) Пирролопиримидины как ингибиторы протеинкиназы
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
ATE437872T1 (de) Proteinkinaseinhibitoren
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
EA200700902A1 (ru) 3-ариламинопиридиновые производные
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
MXPA04004301A (es) Bencimidazoles sustituidos utiles como inhibidores de la proteina cinasa.
NO20082496L (no) Pyrazinderivater
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
MXPA05012247A (es) Derivados de bencimidazol nuevos.
CY1111574T1 (el) Παραγωγα βουτανοϊκου οξεος, διαδικασιες για την παρασκευη τους, φαρμακευτικες συνθεσεις που τα περιλαμβανουν και θεραπευτικες εφαρμογες αυτων
ATE498600T1 (de) Inden derivate als pharmazeutika
MXPA05010020A (es) Derivados de oxamida.
NO20054361D0 (no) Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties